Resources
169 Results (showing 41 - 50)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.
Posted 11/4/2020 (updated 4/3/2024)
The Council of State and Territorial Epidemiologists established the PMP Subcommittee to provide a platform for information exchange and addressing the need for a standardized metrics for opioid surveillance using PMP data. PMP group members identified a need to provide guidance for new PMP data users. Group members collaborated to write and develop a very comprehensive two-part How To Guide that provides instructions for new PMP data users.
Posted 11/4/2020 (updated 4/3/2024)
Thank you for your dedication to supporting all survivors. The goal of this guide is to assist programs and advocates in supporting survivors who use substances by providing practical strategies embedded within an accessible, culturally responsive, and trauma-informed (ACRTI) approach.
Posted 9/15/2021 (updated 4/2/2024)
Background: Opioid overdose has become the leading cause of death among adults between 25 and 54 years old in the U.S. The purpose of this study is to explore the social and relational factors that shape the current opioid overdose epidemic.
Posted 9/15/2021 (updated 4/2/2024)
Background: Rates of fatal overdose (OD) from synthetic opioids rose nearly 60 % from 2016 to 2018. 911 Good Samaritan Laws (GSLs) are an evidenced-based strategy for preventing OD fatality. This study describes patrol officers’ knowledge of their state’s GSL, experience with OD response, and their perspectives on strategies to prevent and respond to opioid OD.
Posted 9/8/2021 (updated 4/2/2024)
Jordana Latozas ACNP, President of Recovery Mobile Clinic, described the mobile medical model and discuss how they are growing and developing in the field
Learning Objectives:
Recognize the current scope of Mobile units focused on Addiction medicine
Recognize the lack of rural area SUD and MAT treatment
Identify difficulties with the Mobile Model
Identify Ways to bring the Mobile Model into mainstream SUD/OUD treatment
Presenter: Jordana Latozas ACNP, President of Recovery Mobile Clinic
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 8/19/2021 (updated 4/2/2024)
Have you ever felt too uncomfortable or weird (not in a nice way) after taking stims? You could have been “overamping.” Stimulants like crack/cocaine and meth can lead to side effects that are unwanted and uncomfortable or potentially dangerous. Knowing what it is and what to do can help you be prepared if it happens.
Overamping happens when the effects of a stimulant become overwhelming, distressing, and/or dangerous.Overamping is specific to “overdosing” on stims like crack, cocaine, or meth. Using the word “overamping” helps to differentiate from an opioid overdose since they are different in how it happens, how it appears, and how to respond.
Posted 8/4/2021 (updated 4/2/2024)